SCHEMBL16409393

SCHEMBL16409393

CCOC1CCNC(c2ccc(C(=O)OC)cc2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.42
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 3/20 0.42
GAA P10253 3/20 0.42
TSHR P16473 3/20 0.42
HPGD P15428 2/20 0.42
CASP1 P29466 2/20 0.42
CASP7 P55210 2/20 0.42
ATM Q13315 2/20 0.42
HTT P42858 3/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GLA P06280 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CFB P00751 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 3/20 0.37
ABL1 P00519 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16400875 1.00 KDM4E (0.42) KDM4EALDH1A1HSD17B10GAATSHR
SCHEMBL20012083 1.00 KDM4E (0.42) KDM4EALDH1A1HSD17B10GAATSHR
Maleic Acid SCHEMBL31677896 0.93 KDM4E (0.38) KDM4EALDH1A1HSD17B10GAATSHR
SCHEMBL16409225 0.90 ALDH1A1 (0.41) KDM4EALDH1A1HSD17B10GAATSHR
SCHEMBL25076857 0.88 KDM4E (0.41) KDM4EALDH1A1HSD17B10GAATSHR
SCHEMBL25619490 0.88 KDM4E (0.41) KDM4EALDH1A1HSD17B10GAATSHR
SCHEMBL26289358 0.87 ALDH1A1 (0.44) KDM4EALDH1A1HSD17B10GAATSHR
SCHEMBL16401331 0.87 ALDH1A1 (0.46) KDM4EALDH1A1HSD17B10GAATSHR
SCHEMBL16400696 0.87 ALDH1A1 (0.46) KDM4EALDH1A1HSD17B10GAATSHR
SCHEMBL16409256 0.87 ALDH1A1 (0.46) KDM4EALDH1A1HSD17B10GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3299365-A1 PIPERIDINYL-INDOLE DERIVATIVES COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF Novartis AG (CH) 2018-03-28 EP disclosed
US-20180009795-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof NOVARTIS AG (CH) 2018-01-11 US disclosed
EP-3022192-B1 PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS NOVARTIS AG (CH) 2017-10-11 EP disclosed
US-9682968-B2 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof NOVARTIS AG (CH) 2017-06-20 US disclosed
US-9682968-B2 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof NOVARTIS AG (CH) 2017-06-20 US disclosed
US-20160152605-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof NOVARTIS AG (CH) 2016-06-02 US disclosed
US-20160152605-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof NOVARTIS AG (CH) 2016-06-02 US disclosed
WO-2015009616-A1 PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS NOVARTIS AG (CH) 2015-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152605-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof CFB, TFPI, TFPI2 KDM4E 3083/4885ALDH1A1 1827/4885HSD17B10 3087/4885
US-20180009795-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof CFB, C5, TFPI KDM4E 2332/4885ALDH1A1 1590/4885HSD17B10 3101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.